A number of leading drug firms have announced plans to cut prices dramatically for life-saving drugs in the developing world.
UK-based Glaxo Smithkline, says it will reduce the cost of its Rotarix vaccine by 67 per cent. It will now cost $5 to immunise a child against rotavirus, a leading cause of diarrhoea.
The price cuts have been broadly welcomed by aid agencies. But Save the Children says it only goes partly in plugging a $3.7bn shortfall needed to produce life-saving drugs.
Al Jazeera spoke to Paul Cook, the head of advocacy at Tearfund.
Source: Al Jazeera